Intranasal Peptide Administration: Complete Guide

Most peptide researchers default to subcutaneous injection without ever considering that for certain compounds, a nasal spray can deliver comparable—or even superior—results. A 2018 study published in Pharmaceutical Research demonstrated that intranasal insulin reached cerebrospinal fluid concentrations 7-fold higher than intravenous delivery at equivalent doses, challenging the long-held assumption that injection is always the gold standard. For a specific subset of peptides, the nose-to-brain pathway offers a direct route that bypasses first-pass metabolism and, in some cases, the blood-brain barrier itself.

This guide covers the science behind intranasal peptide delivery, which peptides are best suited for it, practical preparation techniques, and the bioavailability data researchers should know before choosing their administration route.

The Science Behind Intranasal Delivery

The nasal cavity is far more than a simple air passage. The upper nasal epithelium contains the olfactory region—a roughly 10 cm² area in humans—where olfactory sensory neurons project directly through the cribriform plate into the brain's olfactory bulb. This anatomical shortcut is the foundation of nose-to-brain drug delivery, a concept that has gained significant traction in neuroscience research over the past two decades.

There are three primary transport pathways for intranasally administered compounds. The first is the olfactory nerve pathway, where molecules are transported along olfactory neurons via intracellular or extracellular mechanisms to reach the olfactory bulb and, from there, deeper brain structures. The second is the trigeminal nerve pathway, which innervates the respiratory epithelium of the nasal cavity and projects to the brainstem, providing another direct route to the central nervous system. The third is systemic absorption through the richly vascularized nasal mucosa, which functions similarly to an injection by delivering the peptide into general circulation.

For peptides that target the central nervous system—nootropics, anxiolytics, neuroprotective agents—the first two pathways are particularly valuable. Research by Lochhead and Thorne (2012) demonstrated that intranasal delivery of large molecules including peptides and proteins can achieve brain concentrations that would require orders-of-magnitude higher systemic doses to match. This is why intranasal Semax, Selank, and oxytocin have become subjects of intense research interest.

Bioavailability: Intranasal vs. Injection

Bioavailability is the critical variable when comparing administration routes, and the data varies enormously depending on the peptide in question. Small, relatively lipophilic peptides tend to perform well intranasally, while larger peptides face significant absorption barriers.

The nasal mucosa presents several challenges to peptide absorption: mucociliary clearance sweeps compounds toward the nasopharynx within 15–20 minutes, enzymatic degradation by aminopeptidases and proteases in the nasal epithelium can break down peptides before they absorb, and the tight junctions between epithelial cells restrict paracellular transport of molecules larger than roughly 1,000 Daltons.

The pattern is clear: peptides under roughly 1,000 Da with some degree of lipophilicity tend to perform best intranasally. Semax and Selank were specifically developed with nasal delivery in mind by Russian pharmaceutical researchers, which partly explains their strong intranasal performance. Larger peptides like BPC-157 and most growth hormone secretagogues lack the absorption profile that would make intranasal delivery practical without absorption enhancers.

Best Peptides for Intranasal Administration

Not every peptide is a candidate for nasal delivery. Based on the available research literature and community experience, here are the peptides most commonly and successfully used via the intranasal route.

Semax and NA-Semax

Semax is arguably the poster child for intranasal peptide delivery. Developed at the Institute of Molecular Genetics in Russia, it was designed from the outset as a nasal spray. Semax is a synthetic analog of ACTH(4-10) with a modified C-terminus that improves stability against enzymatic degradation. Its primary researched effects include upregulation of BDNF expression, modulation of serotonergic and dopaminergic systems, and neuroprotection against oxidative stress. The N-acetyl variant (NA-Semax) adds an acetyl group that further enhances stability and may increase potency. Research dosing in the literature typically ranges from 200–600 mcg per administration, delivered 1–3 times daily.

Selank and NA-Selank

Selank is a synthetic analog of the immunomodulatory peptide tuftsin, also developed at Russian research institutes. It has been studied primarily for anxiolytic and nootropic effects, with research demonstrating modulation of GABA-A receptor expression, influence on IL-6 and monoamine metabolism, and a favorable safety profile in preclinical models. Like Semax, it was designed for intranasal use. Reported intranasal bioavailability of 60–80% makes it one of the best-absorbing nasal peptides studied. The N-acetyl form (NA-Selank) offers enhanced enzymatic stability and a potentially prolonged duration of action.

Oxytocin

Intranasal oxytocin has been the subject of hundreds of clinical studies investigating its effects on social cognition, anxiety, trust, and bonding. While systemic bioavailability via the nose is quite low (2–5%), the clinical effects observed in trials strongly suggest meaningful CNS delivery through direct nose-to-brain pathways. Research protocols typically use 20–40 IU delivered via calibrated nasal spray devices. Notably, a 2020 systematic review in Psychoneuroendocrinology found that intranasal oxytocin produced measurable behavioral and neuroimaging effects in the majority of controlled trials, supporting the viability of this delivery route for this particular peptide.

Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a small angiotensin IV analog that has shown remarkable potency in preclinical cognitive research. Its relatively small size and lipophilic hexanoyl group make it theoretically amenable to nasal absorption. Some researchers have explored intranasal delivery, though published bioavailability data specifically for this route remains limited. The compound's potency at picomolar concentrations means that even modest nasal absorption may be functionally relevant.

How to Prepare a Peptide Nasal Spray

Preparing a nasal spray from lyophilized peptide requires attention to sterility, accurate dosing calculations, and appropriate equipment. The following outlines the standard laboratory preparation method documented in research protocols.

Equipment Needed

Researchers typically use a sterile metered-dose nasal spray bottle (most deliver 0.1 mL per actuation), bacteriostatic water (BAC water) as the reconstitution solvent, alcohol swabs for vial tops, and standard syringes for transfer. Some protocols call for sterile saline (0.9% NaCl) instead of BAC water, particularly for sensitive compounds or when benzyl alcohol preservative is a concern.

Dosing Calculations

The math is straightforward but important to get right. If a nasal spray bottle delivers 0.1 mL per pump, and the target dose is 300 mcg per spray, the required concentration is 3 mg/mL (3,000 mcg per mL). For a 5 mg vial of peptide, reconstituting with 1.67 mL of BAC water would yield approximately 3 mg/mL. Most researchers round to convenient volumes and adjust the number of sprays per dose accordingly.